Cantor Fitzgerald Reiterates Overweight on Crinetics Pharmaceuticals, Maintains $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on Crinetics Pharmaceuticals (NASDAQ:CRNX) and maintained a $65 price target.

May 14, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald reaffirms an Overweight rating on Crinetics Pharmaceuticals with a $65 price target, indicating a positive outlook on the stock.
The reiteration of an Overweight rating by a reputable analyst firm like Cantor Fitzgerald, along with a maintained price target of $65, suggests a strong confidence in the company's future performance. This endorsement is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100